SS-31 (Elamipretide) Deep Dive: Mitochondrial Cardioprotection Research
Research Use Only. This article is for scientific and educational reference only. All products are sold for research purposes and are not intended for human or animal consumption.
Overview
SS-31 (also known as Elamipretide, MTP-131, and Bendavia) is a synthetic tetrapeptide (D-Arg-2'6'-Dmt-Lys-Phe-NH2) developed by Hazel Szeto and Peter Schiller at Weill Cornell Medicine. It belongs to the Szeto-Schiller (SS) peptide family, designed specifically to target the inner mitochondrial membrane. SS-31 has been studied in over 20 clinical trials for heart failure, renal disease, and mitochondrial myopathy.
Mechanism of Action
Cardiolipin binding: SS-31's primary mechanism involves selective binding to cardiolipin, a phospholipid found almost exclusively in the inner mitochondrial membrane. Cardiolipin is essential for the structural integrity of the electron transport chain (ETC) complexes and ATP synthase.
ETC complex stabilization: By binding cardiolipin, SS-31 stabilizes the supercomplexes formed by ETC Complexes I, III, and IV (the "respirasome"). This stabilization improves electron transfer efficiency and reduces electron leak, which is the primary source of mitochondrial reactive oxygen species (ROS).
ROS reduction: SS-31 reduces mitochondrial ROS production by improving ETC efficiency, not by direct antioxidant scavenging. This mechanistic distinction is important — SS-31 addresses the source of ROS rather than neutralizing it downstream.
ATP production: By stabilizing ETC supercomplexes, SS-31 improves ATP synthesis efficiency, particularly under conditions of mitochondrial stress (ischemia, aging, disease).
Cardiac Research
Ischemia-reperfusion injury: SS-31 has demonstrated robust cardioprotection in multiple ischemia-reperfusion models. A landmark study in pigs showed that SS-31 administered before reperfusion reduced infarct size by ~40% and preserved left ventricular function.
Heart failure with preserved ejection fraction (HFpEF): A Phase 2 clinical trial (AGED-HFpEF) investigated SS-31 in elderly patients with HFpEF. Results showed significant improvements in exercise capacity (peak VO2) and quality of life scores.
Acute myocardial infarction: The EMBRACE STEMI trial investigated SS-31 in patients undergoing primary PCI for acute MI. While the primary endpoint (infarct size by MRI) was not met in the overall population, a pre-specified subgroup analysis showed significant benefit in patients with longer ischemic times.
Renal Research
Contrast-induced nephropathy: Clinical trials have investigated SS-31 for prevention of contrast-induced acute kidney injury in patients undergoing cardiac catheterization. Results have been mixed across trials.
Chronic kidney disease: Preclinical research has shown that SS-31 reduces renal fibrosis and preserves renal function in CKD models by reducing mitochondrial dysfunction in tubular epithelial cells.
Mitochondrial Myopathy Research
Primary mitochondrial myopathy (PMM): The MMPOWER-3 Phase 3 trial investigated SS-31 in patients with primary mitochondrial myopathy. While the primary endpoint was not met, secondary endpoints showed improvements in fatigue and physical function. A subsequent open-label extension showed sustained benefits.
Comparison with Other Mitochondria-Targeting Peptides
| Parameter | SS-31 (Elamipretide) | MOTS-c | Epithalon | |-----------|---------------------|--------|-----------| | Target | Inner mitochondrial membrane (cardiolipin) | Mitochondrial genome (AMPK) | Telomerase/pineal | | Primary application | Cardioprotection, heart failure | Metabolic regulation | Aging/longevity | | Clinical trials | 20+ trials | Early phase | Russian clinical studies | | Mechanism | ETC stabilization, ROS reduction | AMPK activation | Telomerase activation |
Summary
SS-31 (Elamipretide) represents the most clinically advanced mitochondria-targeting peptide, with over 20 clinical trials across cardiac, renal, and mitochondrial disease indications. Its unique mechanism of cardiolipin binding and ETC supercomplex stabilization makes it a foundational research tool for mitochondrial biology and bioenergetics.
See Also: MOTS-c Research Overview: Mitochondrial Peptide and Metabolic Health | Epithalon Research Overview: Telomeres and Aging
Was this article helpful?
Click a star to rate